Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Invitae Co. stock logo
NVTA
Invitae
$0.00
$0.00
$0.02
▼
$0.02
$80K1.5923.72 million shsN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
$0.02
$0.04
$0.02
▼
$6.66
$306K0.06220,159 shs73 shs
Vicarious Surgical Inc. stock logo
RBOT
Vicarious Surgical
$0.03
-22.9%		$0.09
$0.03
▼
$7.72
$277K1.8666,819 shs55,054 shs
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$0.00
$0.00
$0.00
▼
$0.05
$221K0.11261,475 shs73,281 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Invitae Co. stock logo
NVTA
Invitae
0.00%0.00%0.00%0.00%0.00%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
0.00%-15.50%-62.19%-78.88%-99.66%
Vicarious Surgical Inc. stock logo
RBOT
Vicarious Surgical
-22.88%-22.88%-52.98%-94.12%-99.47%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.00%-33.33%-20.00%-55.56%-80.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Invitae Co. stock logo
NVTA
Invitae
$0.00
$0.00
$0.02
▼
$0.02
$80K1.5923.72 million shsN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
$0.02
$0.04
$0.02
▼
$6.66
$306K0.06220,159 shs73 shs
Vicarious Surgical Inc. stock logo
RBOT
Vicarious Surgical
$0.03
-22.9%		$0.09
$0.03
▼
$7.72
$277K1.8666,819 shs55,054 shs
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$0.00
$0.00
$0.00
▼
$0.05
$221K0.11261,475 shs73,281 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover
The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Invitae Co. stock logo
NVTA
Invitae
0.00%0.00%0.00%0.00%0.00%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
0.00%-15.50%-62.19%-78.88%-99.66%
Vicarious Surgical Inc. stock logo
RBOT
Vicarious Surgical
-22.88%-22.88%-52.98%-94.12%-99.47%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.00%-33.33%-20.00%-55.56%-80.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Invitae Co. stock logo
NVTA
Invitae
0.00
N/AN/AN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
1.00
SellN/AN/A
Vicarious Surgical Inc. stock logo
RBOT
Vicarious Surgical
1.50
ReduceN/AN/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Invitae Co. stock logo
NVTA
Invitae
$481.58M0.00N/AN/A$0.42 per share0.00
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
$5.06M0.06N/AN/A$2.46 per share0.01
Vicarious Surgical Inc. stock logo
RBOT
Vicarious Surgical
N/AN/AN/AN/A$7.89 per shareN/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
$60.32M0.00N/AN/AN/A∞
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Invitae Co. stock logo
NVTA
Invitae
-$3.11B-$5.38N/AN/AN/A-299.14%-6,100.71%-19.68%N/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
-$53.36M-$2.25N/AN/AN/A-825.01%-482.05%-88.90%11/5/2026 (Estimated)
Vicarious Surgical Inc. stock logo
RBOT
Vicarious Surgical
-$63.22M-$6.69N/AN/AN/AN/A-184.13%-112.50%11/17/2026 (Estimated)
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
-$572.84M-$0.17N/AN/AN/AN/AN/AN/A11/6/2026 (Estimated)
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Invitae Co. stock logo
NVTA
Invitae
N/AN/AN/AN/AN/A
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
N/AN/AN/AN/AN/A
Vicarious Surgical Inc. stock logo
RBOT
Vicarious Surgical
N/AN/AN/AN/AN/A
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Invitae Co. stock logo
NVTA
Invitae
N/A
2.39
2.25
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
0.14
0.14
0.14
Vicarious Surgical Inc. stock logo
RBOT
Vicarious Surgical
N/A
4.75
4.75
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Invitae Co. stock logo
NVTA
Invitae
61.28%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
9.45%
Vicarious Surgical Inc. stock logo
RBOT
Vicarious Surgical
47.27%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
0.02%

Insider Ownership

CompanyInsider Ownership
Invitae Co. stock logo
NVTA
Invitae
0.74%
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
9.60%
Vicarious Surgical Inc. stock logo
RBOT
Vicarious Surgical
11.11%
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
2.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Invitae Co. stock logo
NVTA
Invitae
1,700267.01 million284.37 millionNo Data
ProPhase Labs, Inc. stock logo
PRPH
ProPhase Labs
13018.12 million5.44 millionNo Data
Vicarious Surgical Inc. stock logo
RBOT
Vicarious Surgical
2107.12 million5.89 millionNo Data
Sorrento Therapeutics, Inc. stock logo
SRNE
Sorrento Therapeutics
800551.28 million536.95 millionNo Data

Recent News About These Companies

Sorrento Voyage Announces Expanded Luxury Boat Tours and Proposal Experiences Along the Amalfi Coast
January 5, 2026  |  newsfilecorp.comN
Sorrento Therapeutics Inc (SRNE) - Investing.com
July 3, 2025  |  investing.comhttps://www.investing.com/equities/sorrento-therape-opinion
SRNE Sorrento Therapeutics, Inc. - Seeking Alpha
June 29, 2025  |  seekingalpha.comhttps://seekingalpha.com/symbol/SRNE
Sorrento Therapeutics Stock Price, Quotes and Forecasts | OTC:SRNE | Benzinga
April 19, 2025  |  benzinga.comhttps://www.benzinga.com/quote/SRNE
Sorrento Shareholders Lose Discovery Bid Over Judge Relationship
March 28, 2025  |  news.bloomberglaw.comN
Scilex says bankruptcy court extends lockup period on shares of Scilex dividend
January 31, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/scilex-says-bankruptcy-court-extends-lockup-period-on-shares-of-scilex-dividend-1034296170
DSI Introduces Westbury Sorrento Aluminum Railing with Bold Distinctive Mesh Stainless Steel Infills
October 24, 2024  |  newsfilecorp.comN
Sorrento enrols 60 of 80-patient Phase II target for abivertinib in Covid-19; futility analysis potentially in a month, CEO says
August 20, 2024  |  msn.comhttps://www.msn.com/en-us/health/medical/sorrento-enrols-60-of-80-patient-phase-ii-target-for-abivertinib-in-covid-19-futility-analysis-potentially-in-a-month-ceo-says/ar-AA1p7arP
Sorrento Resources to Sell Three Newfoundland Properties to Gold Hunter
May 29, 2024  |  newsfilecorp.comN
Sorrento Therapeutics Inc (SRNE)
May 25, 2024  |  investing.comhttps://www.investing.com/equities/sorrento-therape-opinion/3
Sorrento Resources Announces Appointment of Alex Bugden as a Director and Qualified Person
May 8, 2024  |  newsfilecorp.comN
DSI Introduces Westbury(R) Sorrento Aluminum and Stainless Steel Mesh Railing
May 1, 2024  |  newsfilecorp.comN
Sorrento Therapeutics Inc SRNE
April 26, 2024  |  morningstar.comM
Sorrento Therapeutics Wins Appeal Over Covid Treatment Remarks
March 27, 2024  |  news.bloomberglaw.comN
Sorrento Therapeutics Wins Appeal Over Covid Treatment Remarks
March 27, 2024  |  news.bloomberglaw.comN
Sorrento Defeats DOJ Effort to Move Bankruptcy Out of Texas (1)
March 12, 2024  |  news.bloomberglaw.comN
Judge Declines to Dismiss Sorrento Therapeutics Bankruptcy Case
March 12, 2024  |  wsj.comhttps://www.wsj.com/articles/judge-declines-to-dismiss-sorrento-therapeutics-bankruptcy-case-8321bd69
Sorrento Therapeutics
February 7, 2024  |  pharmaphorum.comP
5 Sanders Cove, Sorrento WA 6020
January 18, 2024  |  domain.com.auD
Sorrento Therapeutics, Inc. (0L85.L)
January 9, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/quote/0L85.L/history/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
A quantum computing processor glows inside a gold-plated dilution refrigerator in a research laboratory.
The Quantum Race Is Heating Up—And 2 Small Players Stand Out
By Nathan Reiff | August 17, 2026
NVIDIA logo over a computer chip, server racks, and an upward-trending green stock price chart.
NVIDIA’s Blockbuster Quarter May Still Undersell How Big the AI Buildout Is
By Thomas Hughes | August 27, 2026
Illustration of a computer chip on a circuit board with an upward green stock chart line in a server room.
Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
By Thomas Hughes | August 31, 2026
Illustration of an upward-trending stock chart line overlaid on a city skyline of office towers at sunset.
Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally
By Nathan Reiff | August 30, 2026
Intuit logo displayed over a desk with a laptop, coffee mug, notebook, plant, and financial chart printout.
Intuit’s Earnings Reset May Be More Pivot Than Plunge
By Jeffrey Neal Johnson | August 28, 2026
Invitae stock logo

Invitae NYSE:NVTA

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.

ProPhase Labs stock logo

ProPhase Labs NASDAQ:PRPH

$0.02 0.00 (0.00%)
As of 09/11/2026

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

Vicarious Surgical stock logo

Vicarious Surgical NYSE:RBOT

$0.03 -0.01 (-22.88%)
As of 09/11/2026 03:48 PM Eastern

Vicarious Surgical Inc. operates as a robotics technology company in the United States. The company focuses on developing and commercializing Vicarious System, a single-incision surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. Vicarious Surgical Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Sorrento Therapeutics stock logo

Sorrento Therapeutics NASDAQ:SRNE

$0.0004 0.00 (0.00%)
As of 09/11/2026 03:31 PM Eastern

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas